Status:
COMPLETED
Examination of Quantitative Electroencephalographic (QEEG) Biomarkers in Huntington's Disease
Lead Sponsor:
University of California, Los Angeles
Collaborating Sponsors:
High Q Foundation
Conditions:
Huntington's Disease
Eligibility:
All Genders
21-85 years
Brief Summary
The pace of basic science research defining the mechanisms of selective neuronal degeneration in Huntington disease (HD) has far exceeded the pace of translation of this information into clinically ef...
Detailed Description
We will examine three subject groups in this study: those with mild HD, those with moderate HD, and normal controls. Fifteen subjects will be examined in each group, for an overall total of forty-five...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- Subjects affected by HD or those who are at risk for HD by virtue of having a first-degree relative with the illness, methamphetamine abuse or dependence, as well as normal controls, can participate.
- All subjects will be above the age of 21.
- Subjects will be recruited from clinical settings, and will also be self-referred.
- Exclusion criteria:
- Individuals with pacemakers, infusion pumps, or metallic shrapnel will be excluded from MRI assessments.
- Such implanted metals may be attracted by the MRI machine and put the individual at risk.
- Moreover, individuals with a history of brain surgery and/or skull fracture will also be excluded.
Exclusion
Key Trial Info
Start Date :
September 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 1 2008
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT00670709
Start Date
September 1 2006
End Date
February 1 2008
Last Update
November 9 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
UCLA Laboratory of Brain, Behavior,a nd PHarmacology
Los Angeles, California, United States, 90024